Premium
Reduction in blood glucose values following indomethacin therapy for patent ductus arteriosus
Author(s) -
Hosono SHIGEHARU,
Ohno TUTOMU,
Nagoshi HIROFUMI KIMOTO, REN,
Shimizu MASAKI,
Nozawa MASAYO
Publication year - 1999
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1046/j.1442-200x.1999.01125.x
Subject(s) - medicine , ductus arteriosus , hypoglycemia , anesthesia , endocrinology , diabetes mellitus
Purpose : To evaluate the effects of indomethacin on blood glucose values in premature infants with patent ductus arteriosus (PDA). Methods : Twenty‐five very low birthweight infants with PDA were given 0.2 mg/kg, i.v., indomethacin for up to three doses. We examined the relationship between blood glucose values and glucose infusion rate before and after indomethacin therapy. Results : There was a significant reduction in blood glucose values between 12 and 96 h following i.v. indomethacin therapy. Eleven of 25 infants (44%) had blood glucose values below 40 mg/dL between 12 and 60 h (mean 32.7 h) after the initial dose. Although the glucose infusion rate during the first 12 h was constant (3.56~0.98 mg/kg per min), the blood glucose values decreased from 96~32 mg/dL at the starting point to 75~29 mg/dL at 12 h (P <0.05). The maximum blood glucose reduction was 51.6~34.7 mg/dL and the maximum blood glucose reduction rate was 50.4~20.2%. Conclusions : The results suggest that blood glucose values should be measured at least every 6 h for 72 h until they stabilize in order to prevent unexpected hypoglycemia.